We are live on ! Find out more
STRO icon

Sutro Biopharma

134 hedge funds and large institutions have $819M invested in Sutro Biopharma in 2020 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 45 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

369% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 13

200% more funds holding in top 10

Funds holding in top 10: 26 (+4)

169% more capital invested

Capital invested by funds: $304M → $819M (+$515M)

150% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 18

96% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $763K

56% more funds holding

Funds holding: 86134 (+48)

0.14% more ownership

Funds ownership: 8.51%8.66% (+0.14%)

Holders
134
Holders Change
+48
Holders Change %
+55.81%
% of All Funds
2.37%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.11%
New
61
Increased
45
Reduced
18
Closed
13
Calls
$1.5M
Puts
$763K
Net Calls
+$732K
Net Calls Change
+$732K
Name Holding Trade Value Shares
Change
Change in
Stake
Verition Fund Management
26
Verition Fund Management
Connecticut
$7.07M +$1.99M +12,007 +58%
OM
27
Opaleye Management
Massachusetts
$7M +$2.92M +17,620 +121%
Northern Trust
28
Northern Trust
Illinois
$6.82M +$1.55M +9,347 +42%
Marshall Wace
29
Marshall Wace
United Kingdom
$6.8M +$5.18M +31,310 New
PCM
30
Pentwater Capital Management
Florida
$6.18M -$1.5M -9,050 -24%
ACM
31
Altium Capital Management
New York
$6.01M +$4.58M +27,672 New
Millennium Management
32
Millennium Management
New York
$5.85M -$823K -4,973 -16%
PHP
33
Parkman Healthcare Partners
Connecticut
$5.79M +$938K +5,665 +27%
N
34
Nuveen
North Carolina
$5.74M +$2.56M +15,488 +142%
DCM
35
Driehaus Capital Management
Illinois
$5.66M +$3.23M +19,506 +298%
Barclays
36
Barclays
United Kingdom
$5M -$149K -901 -4%
SFM
37
Sphera Funds Management
Israel
$4.38M +$3.34M +20,160 New
AAA
38
Affinity Asset Advisors
New York
$4.34M +$3.31M +20,000 New
SCM
39
Silverarc Capital Management
Massachusetts
$4.02M +$3.06M +18,500 New
Janus Henderson Group
40
Janus Henderson Group
United Kingdom
$3.96M +$445K +2,689 +17%
WP
41
Woodline Partners
California
$3.96M +$3.02M +18,218 New
AIIC
42
AJU IB Investment Company
South Korea
$3.8M +$2.9M +17,500 New
ECM
43
Endurant Capital Management
California
$3.73M -$4.8M -29,012 -63%
ACM
44
Asymmetry Capital Management
California
$3.42M +$2.61M +15,758 New
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$3.42M +$1.73M +10,429 +197%
KCM
46
Kennedy Capital Management
Missouri
$3.26M +$2.49M +15,028 New
Victory Capital Management
47
Victory Capital Management
Texas
$3.17M +$79.1K +478 +3%
JGC
48
J. Goldman & Co
New York
$3.14M +$2.39M +14,462 New
MS
49
Maven Securities
Jersey
$3.06M +$2.32M +14,000 New
IBT
50
International Biotechnology Trust
United Kingdom
$3.01M

STRO Hedge Fund Activity: Q4 2020 in Review

134 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2020, worth a combined $819M — up 169% from $304M a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new STRO positions and 13 closed out — a net gain of 48 holders — while 45 added to existing stakes and 18 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $36.9M. The largest seller was EcoR1 Capital, cutting an estimated $50M.

  • 134 institutional investors held Sutro Biopharma (STRO) as of Q4 2020, up from 86 in Q3 2020.
  • Funds reported $819M of Sutro Biopharma stock for Q4 2020, up 169% quarter-over-quarter.
  • 61 funds opened new Sutro Biopharma positions in Q4 2020 and 13 closed out, a net change of +48 holders.
  • The largest Sutro Biopharma buyer in Q4 2020 was Franklin Resources, an estimated $36.9M added.
  • The largest Sutro Biopharma seller in Q4 2020 was EcoR1 Capital, an estimated $50M sold.

Based on aggregated 13F filings for Q4 2020.